UBS reiterates Buy for Intuitive Surgical stock at USD 500

Published on 10/14/2026 at 12:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 2.89 billion, up 18.50 percent. Intuitive Surgical stock costs EUR 377.30 on October 14, 2026, 25.71 percent below high.

Analyst view ahead of results

UBS maintained its USD 500.00 target on October 13, 2026.
Second-quarter revenue reached USD 2.89 billion, up 18.50 percent year over year.
Intuitive Surgical stock traded at EUR 377.30 at 12:04 p.m. CEST at Lang & Schwarz on October 14, 2026.
Third-quarter results are scheduled for October 20, 2026.

Extreme Makrofotografie einer miniaturisierten chirurgischen Roboterarmspitze mit Nadelhalter-Handgelenk, feinen Kabelzügen und präzisionsgefrästen Titangelenken, flache Schärfentiefe, metallisch-blaue Töne — Intuitive Surgical US46120E6023 Makroaufnahme zeigt miniaturisierten Roboter Endeffektor mit präziser feiner Gelenkmechanik, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at EUR 377.30 at Lang & Schwarz on October 14, 2026 at 12:04 p.m. CEST. UBS maintained a Buy rating and a USD 500.00 price target on October 13, ahead of Intuitive Surgical's third-quarter results scheduled for October 20, 2026.

UBS keeps its USD 500 target

According to Investing.com on October 13, 2026, UBS retained its Buy view and USD 500.00 target. The note said concerns about procedure volumes appeared overly cautious and cited healthy channel checks.

The report also identified a roughly 4.00 percent headwind from Intuitive Surgical's Extended Use Program in 2027. That factor gives the upcoming results a clear test: procedure growth must offset a known pressure on the business.

What does the latest quarter show?

MarketBeat reported that Intuitive Surgical delivered USD 2.80 adjusted earnings per share and USD 2.89 billion in revenue in the second quarter of 2026, versus consensus of USD 2.48 and USD 2.83 billion. Revenue increased 18.40 percent year over year.

The revenue comparison matters because the company enters the October 20 report with evidence of double-digit expansion but also with a high valuation backdrop. The latest standardized financial data show second-quarter operating margin of 34.00 percent and operating cash flow of USD 1.06 billion.

Results date sets the next test

The company investor-relations page lists the third-quarter earnings conference call for October 20, 2026 at 1:30 p.m. PDT. Its recent release calendar also lists a September 8, 2026 meta-analysis covering outcomes associated with da Vinci surgery across 13 benign conditions, linking the clinical narrative to the company's core platform.

Intuitive Surgical's stock was valued at USD 149.8 billion on October 12, 2026, while the euro quote's 52-week range was EUR 291.40 to EUR 507.90 as of October 13, 2026. EUR 377.30 stands 25.71 percent below that high, leaving the October 20 report as the next dated event with a direct earnings comparison.

Quote remains below the yearly high

At Lang & Schwarz, Intuitive Surgical stock was trading at EUR 377.30 on October 14, 2026 at 12:04 p.m. CEST. The 52-week range was EUR 291.40 to EUR 507.90 as of October 13, 2026. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.